Prior clinical trials evaluating treatment of breast cancer in the metastatic setting demonstrated that breast cancer patients with low HER2 expression responded well to trastuzumab deruxtecan with increased overall patient survival [35]. This evidence concerns the gene ERBB2 and breast cancer.